Free Trial

Daxor (DXR) Stock Price, News & Analysis

Daxor logo
$9.33 +0.04 (+0.43%)
As of 03:50 PM Eastern

About Daxor Stock (NASDAQ:DXR)

Key Stats

Today's Range
$9.10
$9.33
50-Day Range
$7.20
$9.86
52-Week Range
$6.55
$10.00
Volume
527 shs
Average Volume
5,873 shs
Market Capitalization
$45.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$25.00
Consensus Rating
Buy

Company Overview

Daxor Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
83rd Percentile Overall Score

DXR MarketRank™: 

Daxor scored higher than 83% of companies evaluated by MarketBeat, and ranked 187th out of 939 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Daxor has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Daxor has received no research coverage in the past 90 days.

  • Read more about Daxor's stock forecast and price target.
    • Percentage of Shares Shorted

      0.60% of the float of Daxor has been sold short.
    • Short Interest Ratio / Days to Cover

      Daxor has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
    • Change versus previous month

      Short interest in Daxor has recently decreased by 5.34%, indicating that investor sentiment is improving significantly.
    • Dividend Yield

      Daxor does not currently pay a dividend.

    • Dividend Growth

      Daxor does not have a long track record of dividend growth.

    • Percentage of Shares Shorted

      0.60% of the float of Daxor has been sold short.
    • Short Interest Ratio / Days to Cover

      Daxor has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.
    • Change versus previous month

      Short interest in Daxor has recently decreased by 5.34%, indicating that investor sentiment is improving significantly.
    • News Sentiment

      Daxor has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.00 average news sentiment score of Medical companies.
    • News Coverage This Week

      MarketBeat has tracked 1 news article for Daxor this week, compared to 1 article on an average week.
    • Insider Buying vs. Insider Selling

      In the past three months, Daxor insiders have not sold or bought any company stock.

    • Percentage Held by Insiders

      59.50% of the stock of Daxor is held by insiders. A high percentage of insider ownership can be a sign of company health.

    • Percentage Held by Institutions

      Only 1.34% of the stock of Daxor is held by institutions.

    • Read more about Daxor's insider trading history.
    Receive DXR Stock News and Ratings via Email

    Sign-up to receive the latest news and ratings for Daxor and its competitors with MarketBeat's FREE daily newsletter.

    DXR Stock News Headlines

    A grave, grave error.
    I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
    See More Headlines

    DXR Stock Analysis - Frequently Asked Questions

    Daxor's stock was trading at $7.69 at the beginning of 2025. Since then, DXR stock has increased by 21.3% and is now trading at $9.33.

    Shares of DXR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

    Based on aggregate information from My MarketBeat watchlists, some other companies that Daxor investors own include Merck & Co., Inc. (MRK), Novavax (NVAX), Arbutus Biopharma (ABUS), Abbott Laboratories (ABT), Abiomed (ABMD), Aclaris Therapeutics (ACRS) and

    Company Calendar

    Today
    7/14/2025
    Fiscal Year End
    12/31/2025

    Industry, Sector and Symbol

    Stock Exchange
    NASDAQ
    Sector
    Medical
    Industry
    MED - OUTP/HM CRE
    Sub-Industry
    Medical Equipment
    Current Symbol
    NASDAQ:DXR
    CIK
    27367
    Employees
    37
    Year Founded
    N/A

    Price Target and Rating

    High Price Target
    $25.00
    Low Price Target
    $25.00
    Potential Upside/Downside
    +169.1%
    Consensus Rating
    Buy
    Rating Score (0-4)
    3.00
    Research Coverage
    1 Analysts

    Profitability

    EPS (Trailing Twelve Months)
    N/A
    Trailing P/E Ratio
    N/A
    Forward P/E Ratio
    N/A
    P/E Growth
    N/A
    Net Income
    N/A
    Net Margins
    N/A
    Pretax Margin
    N/A
    Return on Equity
    N/A
    Return on Assets
    N/A

    Debt

    Debt-to-Equity Ratio
    N/A
    Current Ratio
    N/A
    Quick Ratio
    N/A

    Sales & Book Value

    Annual Sales
    N/A
    Price / Sales
    N/A
    Cash Flow
    N/A
    Price / Cash Flow
    N/A
    Book Value
    N/A
    Price / Book
    N/A

    Miscellaneous

    Outstanding Shares
    4,840,000
    Free Float
    1,959,000
    Market Cap
    $44.96 million
    Optionable
    Not Optionable
    Beta
    -0.07
    The Best High-Yield Dividend Stocks for 2025 Cover

    Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

    Get This Free Report

    This page (NASDAQ:DXR) was last updated on 7/14/2025 by MarketBeat.com Staff
    From Our Partners